Anti-Human VEGF-A (Brolucizumab Biosimilar)
Catalog #500011
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500011 | 1 mg | $200.00 | ||
| 500011 | 5 mg | $600.00 | ||
| 500011 | 20 mg | $1,400.00 |
Product Details
Brolucizumab biosimilar is a humanized single-chain variable fragment (scFv) monoclonal antibody designed as an alternative to the reference biologic Brolucizumab (Beovu®). It specifically binds to and inhibits vascular endothelial growth factor A (VEGF-A), a key regulator of abnormal blood vessel growth and vascular leakage in ocular diseases. This biosimilar is intended for preclinical research and development in ophthalmology, particularly in conditions like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Specifications
| Clone | Brolucizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human VEGF-A |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |